Microbial ColonizationNCT05375383
Microbial Colonization of Oral Probiotics
A study testing Streptococcus salivarius K12 lozenge, Probiotic S. salivarius K12 lozenges containing prebiotic A and Probiotic S. salivarius K12 lozenges containing prebiotic B in people with Microbial Colonization, run by BLIS Technologies Limited at 1 site in New Zealand.
Trial summary
The aim of this study is to evaluate the colonization efficacy of probiotic lozenges and powders containing specific prebiotics in healthy adults Read more about this study
- Who is it for?
- Ages 18 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Microbial Colonization
- What is being tested?
- Streptococcus salivarius K12 lozenge, Probiotic S. salivarius K12 lozenges containing prebiotic A and Probiotic S. salivarius K12 lozenges containing prebiotic B
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteNew Zealand
- Study dates
- 15 Jun 2022to 15 Sep 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Male or Female 18y - 80y age
- In general good health 18 - 80 years of age.
- Practice good oral hygiene.
Who cannot join
- Have a history of autoimmune disease or are immunocompromised.
- Are on concurrent antibiotic therapy or regular antibiotic use within last 1 week
- History of allergy (e.g. dairy).
Trial locations and contacts
1 site in 1 country.
New Zealand1 site, 1 recruiting
- Recruiting
Blis Technologies Ltd
Dunedin, Otago, 9012
John D Hale, PhD, +6434740988, john.hale@blis.co.nz
Rohit Jain, PhD, +6434740988, rohit.jain@blis.co.nz
About this study
Official title: Assessment of Colonisation of Probiotic Bacterium Streptococcus Salivarius in the Oral Cavity
The aim of this study is to evaluate the colonization efficacy of probiotic lozenges and powders containing specific prebiotics in healthy adults
Read the detailed description
This is a double-blind, randomized controlled colonization pilot study with no cross over to evaluate the colonization efficacy of lozenges and powders containing two different commercially available probiotic bacteria (S. salivarius K12 ) or S. salivarius M18 with or without 2 different prebiotic sugars or their combinations.
Participants will be randomly assigned to one of the 12 groups consuming probiotic lozenge or powder containing Streptococcus salivarius K12 or S. salivarius M18 with or without prebiotics (e.g. sugars that may promote probiotic activity) over a seven day period. Saliva samples will be collected at predetermined time points pre and post intervention. Colonisation efficacy will be determined by enumerating the probiotic in the saliva samples using standard microbiological techniques.
- Conditions
- Microbial Colonization
- Being tested
- Streptococcus salivarius K12 lozenge, Probiotic S. salivarius K12 lozenges containing prebiotic A, Probiotic S. salivarius K12 lozenges containing prebiotic B, Probiotic S. salivarius K12 lozenges containing prebiotics A and B, Probiotic S. salivarius K12 powder
- Keywords
- Streptococcus salivarius K12, Probiotic, microbial colonization, oral probiotic, lozenges, powder, prebiotic, Streptococcus salivarius M18
- Medical subject headings
- Communicable Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Streptococcus salivarius K12 lozengeDietary supplement
In this study, a lozenge will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
Probiotic S. salivarius K12 lozenges containing prebiotic ADietary supplement
In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
Probiotic S. salivarius K12 lozenges containing prebiotic BDietary supplement
In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
Probiotic S. salivarius K12 lozenges containing prebiotics A and BDietary supplement
In this study, a lozenge containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
Probiotic S. salivarius K12 powderDietary supplement
In this study, a powder will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
Probiotic S. salivarius K12 powder containing prebiotic ADietary supplement
In this study, a powder containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
Probiotic S. salivarius K12 powder containing prebiotic BDietary supplement
In this study, a powder containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
Probiotic S. salivarius K12 powder containing prebiotics A and BDietary supplement
In this study, a powder containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
Probiotic S. salivarius M18 lozengesDietary supplement
In this study, a lozenge containing will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
Probiotic S. salivarius M18 lozenges containing prebiotic ADietary supplement
In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
Probiotic S. salivarius M18 lozenges containing prebiotic BDietary supplement
In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
Probiotic S. salivarius M18 + lozenges containing prebiotic A and BDietary supplement
In this study, a lozenge containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
| Study group | Role | What they receive |
|---|---|---|
| Streptococcus salivarius K12 lozenge | Active comparator | Streptococcus salivarius K12 lozenge Receives: Dietary Supplement: Streptococcus salivarius K12 lozenge |
| Probiotic S. salivarius K12 lozenges containing prebiotic A | Active comparator | Streptococcus salivarius K12 lozenge with prebiotic Receives: Dietary Supplement: Probiotic S. salivarius K12 lozenges containing prebiotic A |
| Probiotic S. salivarius K12 lozenges containing prebiotic B | Active comparator | Streptococcus salivarius K12 lozenge with prebiotic Receives: Dietary Supplement: Probiotic S. salivarius K12 lozenges containing prebiotic B |
| Probiotic S. salivarius K12 lozenges containing prebiotic A and B | Active comparator | Streptococcus salivarius K12 Receives: Dietary Supplement: Probiotic S. salivarius K12 lozenges containing prebiotics A and B |
| Probiotic S. salivarius K12 powder | Active comparator | Streptococcus salivarius K12 powder Receives: Dietary Supplement: Probiotic S. salivarius K12 powder |
| Probiotic S. salivarius K12 powder containing prebiotic A | Active comparator | Streptococcus salivarius K12 powder with prebiotic Receives: Dietary Supplement: Probiotic S. salivarius K12 powder containing prebiotic A |
| Probiotic S. salivarius K12 powder containing prebiotic B | Active comparator | Streptococcus salivarius K12 powder with prebiotic Receives: Dietary Supplement: Probiotic S. salivarius K12 powder containing prebiotic B |
| Probiotic S. salivarius K12 powder containing prebiotic A and B | Active comparator | Streptococcus salivarius K12 powder with prebiotic Receives: Dietary Supplement: Probiotic S. salivarius K12 powder containing prebiotics A and B |
| Probiotic S. salivarius M18 lozenges | Active comparator | Streptococcus salivarius M18 lozenge Receives: Dietary Supplement: Probiotic S. salivarius M18 lozenges |
| Probiotic S. salivarius M18 lozenges containing prebiotic A | Active comparator | Streptococcus salivarius M18 lozenge with prebiotic Receives: Dietary Supplement: Probiotic S. salivarius M18 lozenges containing prebiotic A |
| Probiotic S. salivarius M18 lozenges der containing prebiotic B | Active comparator | Streptococcus salivarius M18 lozenge with prebiotic Receives: Dietary Supplement: Probiotic S. salivarius M18 lozenges containing prebiotic B |
| Probiotic S. salivarius M18 + lozenges containing prebiotic A and B | Active comparator | Streptococcus salivarius M18 lozenge with prebiotic Receives: Dietary Supplement: Probiotic S. salivarius M18 + lozenges containing prebiotic A and B |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in microbial colonization from baseline (Day 0) to 1 hour for S. salivarius K12 lozenges
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius K12 with or without prebiotics from a lozenge format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to one hour after later across different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
Measured: 1 hour
Change in microbial colonization from baseline (Day 0) to 8 hours or S. salivarius K12 lozenges
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius K12 with or without prebiotics from a lozenge format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to eight hours after later across different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
Measured: 8 hour
Change in microbial colonization from baseline (Day 0) to 24 hours or S. salivarius K12 lozenges
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius K12 with or without prebiotics from a lozenge format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to 24 hours after later across different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
Measured: 24 hour
Change in microbial colonization from baseline (Day 0) to 48 hours or S. salivarius K12 lozenges
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius K12 with or without prebiotics from a lozenge format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to 48hours after later across different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
Measured: 48 hour
in microbial colonization from baseline (Day 0) to 1 hour for S. salivarius K12 powder format
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius K12 with or without prebiotics from a powder format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to one hour after later across two different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
Measured: 1 hour
in microbial colonization from baseline (Day 0) to 8 hour for S. salivarius K12 powder format
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius K12 with or without prebiotics from a powder format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to 8 hours after later across two different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
Measured: 8 hours
in microbial colonization from baseline (Day 0) to 24 hours for S. salivarius K12 powder format
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius K12 with or without prebiotics from a powder format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to 24 hours after later across two different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
Measured: 24 hours
in microbial colonization from baseline (Day 0) to 48 hours for S. salivarius K12 powder format
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius K12 with or without prebiotics from a powder format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to 48 hours after later across two different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
Measured: 48 hours
Change in microbial colonization from baseline (Day 0) to 1 hour for S. salivarius M18 lozenges
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius M18 with or without prebiotics from a lozenge format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to one hour after later across different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
Measured: 1 hour
Change in microbial colonization from baseline (Day 0) to 8 hours for S. salivarius M18 lozenges
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius M18 with or without prebiotics from a lozenge format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to 8 hour after later across different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
Measured: 8 hour
Change in microbial colonization from baseline (Day 0) to 24 hours for S. salivarius M18 lozenges
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius M18 with or without prebiotics from a lozenge format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to 24 hour after later across different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
Measured: 24 hour
Change in microbial colonization from baseline (Day 0) to 48 hours for S. salivarius M18 lozenges
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius M18 with or without prebiotics from a lozenge format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to 48 hour after later across different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
Measured: 48 hour
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 May 2022
- Study start15 Jun 2022 (estimated)
- Primary completion31 Aug 2022 (estimated)
- Study completion15 Sep 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for Microbial ColonizationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomly assigned to one of the 12 groups consuming powder or lozenges containing Streptococcus salivarius K12 or S. salivarius M18 with or without prebiotic: Probiotic S. salivarius K12 lozenges Probiotic S. salivarius K12 lozenges containing prebiotic A Probiotic S. salivarius K12 lozenges containing prebiotic B Probiotic S. salivarius K12 lozenges containing prebiotic A and B Probiotic S. salivarius K12 powder Probiotic S. salivarius K12 powder containing prebiotic A Probiotic S. salivarius K12 powder containing prebiotic B Probiotic S. salivarius K12 powder containing prebiotic A and B Probiotic S. salivarius M18 lozenges Probiotic S. salivarius M18 lozenges containing prebiotic A Probiotic S. salivarius M18 lozenges der containing prebiotic B Probiotic S. salivarius M18 + lozenges containing prebiotic A and B
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- BLIS Technologies Limited
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- John D Hale, PhD, Study director, Blis Technologies LtdRohit Jain, PhD, Principal investigator, Blis Technologies Ltd, Dunedin, New ZealandJohn R Tagg, PhD, Principal investigator, Blis Technologies Ltd, Dunedin, New Zealand
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05375383
- Sponsor's protocol ID
- BLTCT2022/3
- Status last verified
- May 2022
- First submitted
- 11 May 2022
- Last updated
- 16 May 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data and information included in the Protocol and Clinical Study Report will be shared to other researchers and/or in publications in due course.
Publications
Hyink O, Wescombe PA, Upton M, Ragland N, Burton JP, Tagg JR. Salivaricin A2 and the novel lantibiotic salivaricin B are encoded at adjacent loci on a 190-kilobase transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Appl Environ Microbiol. 2007 Feb;73(4):1107-13. doi: 10.1128/AEM.02265-06. Epub 2006 Dec 28.
PubMed 17194838Burton JP, Chilcott CN, Wescombe PA, Tagg JR. Extended Safety Data for the Oral Cavity Probiotic Streptococcus salivarius K12. Probiotics Antimicrob Proteins. 2010 Oct;2(3):135-44. doi: 10.1007/s12602-010-9045-4.
PubMed 26781236Gregori G, Righi O, Risso P, Boiardi G, Demuru G, Ferzetti A, Galli A, Ghisoni M, Lenzini S, Marenghi C, Mura C, Sacchetti R, Suzzani L. Reduction of group A beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study. Ther Clin Risk Manag. 2016 Jan 19;12:87-92. doi: 10.2147/TCRM.S96134. eCollection 2016.
PubMed 26855579Di Pierro F, Adami T, Rapacioli G, Giardini N, Streitberger C. Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults. Expert Opin Biol Ther. 2013 Mar;13(3):339-43. doi: 10.1517/14712598.2013.758711. Epub 2013 Jan 4.
PubMed 23286823Di Pierro F, Colombo M, Zanvit A, Rottoli AS. Positive clinical outcomes derived from using Streptococcus salivarius K12 to prevent streptococcal pharyngotonsillitis in children: a pilot investigation. Drug Healthc Patient Saf. 2016 Nov 21;8:77-81. doi: 10.2147/DHPS.S117214. eCollection 2016.
PubMed 27920580Di Pierro F, Colombo M, Giuliani MG, Danza ML, Basile I, Bollani T, Conti AM, Zanvit A, Rottoli AS. Effect of administration of Streptococcus salivarius K12 on the occurrence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old children. Eur Rev Med Pharmacol Sci. 2016 Nov;20(21):4601-4606.
PubMed 27874935Di Pierro F, Zanvit A, Nobili P, Risso P, Fornaini C. Cariogram outcome after 90 days of oral treatment with Streptococcus salivarius M18 in children at high risk for dental caries: results of a randomized, controlled study. Clin Cosmet Investig Dent. 2015 Oct 3;7:107-13. doi: 10.2147/CCIDE.S93066. eCollection 2015.
PubMed 26491371Bardellini E, Amadori F, Gobbi E, Ferri A, Conti G, Majorana A. Does Streptococcus Salivarius Strain M18 Assumption Make Black Stains Disappear in Children? Oral Health Prev Dent. 2020 Apr 3;18(2):161-164. doi: 10.3290/j.ohpd.a43359.
PubMed 32099975
Study at a glance
From the registry record, last updated by the sponsor on 16 May 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Colonisation of Probiotic Bacterium Streptococcus Salivarius in the Oral Cavity
- ClinicalTrials.gov ID
- NCT05375383
- Acronym / sponsor ID
- BLTCT2022/3
- Conditions
- Microbial Colonization
- Keywords
- Streptococcus salivarius K12, Probiotic, microbial colonization, oral probiotic, lozenges, powder, prebiotic, Streptococcus salivarius M18
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- BLIS Technologies LimitedIndustry (pharma, biotech, devices)
- Study start
- 15 Jun 2022 (estimated)
- Primary completion
- 31 Aug 2022 (estimated)
- Study completion
- 15 Sep 2022 (estimated)
- First posted
- 16 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to evaluate the colonization efficacy of probiotic lozenges and powders containing specific prebiotics in healthy adults
Detailed description
This is a double-blind, randomized controlled colonization pilot study with no cross over to evaluate the colonization efficacy of lozenges and powders containing two different commercially available probiotic bacteria (S. salivarius K12 ) or S. salivarius M18 with or without 2 different prebiotic sugars or their combinations.
Participants will be randomly assigned to one of the 12 groups consuming probiotic lozenge or powder containing Streptococcus salivarius K12 or S. salivarius M18 with or without prebiotics (e.g. sugars that may promote probiotic activity) over a seven day period. Saliva samples will be collected at predetermined time points pre and post intervention. Colonisation efficacy will be determined by enumerating the probiotic in the saliva samples using standard microbiological techniques.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 12
- Model description
- Participants will be randomly assigned to one of the 12 groups consuming powder or lozenges containing Streptococcus salivarius K12 or S. salivarius M18 with or without prebiotic: Probiotic S. salivarius K12 lozenges Probiotic S. salivarius K12 lozenges containing prebiotic A Probiotic S. salivarius K12 lozenges containing prebiotic B Probiotic S. salivarius K12 lozenges containing prebiotic A and B Probiotic S. salivarius K12 powder Probiotic S. salivarius K12 powder containing prebiotic A Probiotic S. salivarius K12 powder containing prebiotic B Probiotic S. salivarius K12 powder containing prebiotic A and B Probiotic S. salivarius M18 lozenges Probiotic S. salivarius M18 lozenges containing prebiotic A Probiotic S. salivarius M18 lozenges der containing prebiotic B Probiotic S. salivarius M18 + lozenges containing prebiotic A and B
| Arm | Type | Receives |
|---|---|---|
| Streptococcus salivarius K12 lozenge | Active comparator | Dietary Supplement: Streptococcus salivarius K12 lozengeStreptococcus salivarius K12 lozenge |
| Probiotic S. salivarius K12 lozenges containing prebiotic A | Active comparator | Dietary Supplement: Probiotic S. salivarius K12 lozenges containing prebiotic AStreptococcus salivarius K12 lozenge with prebiotic |
| Probiotic S. salivarius K12 lozenges containing prebiotic B | Active comparator | Dietary Supplement: Probiotic S. salivarius K12 lozenges containing prebiotic BStreptococcus salivarius K12 lozenge with prebiotic |
| Probiotic S. salivarius K12 lozenges containing prebiotic A and B | Active comparator | Dietary Supplement: Probiotic S. salivarius K12 lozenges containing prebiotics A and BStreptococcus salivarius K12 |
| Probiotic S. salivarius K12 powder | Active comparator | Dietary Supplement: Probiotic S. salivarius K12 powderStreptococcus salivarius K12 powder |
| Probiotic S. salivarius K12 powder containing prebiotic A | Active comparator | Dietary Supplement: Probiotic S. salivarius K12 powder containing prebiotic AStreptococcus salivarius K12 powder with prebiotic |
| Probiotic S. salivarius K12 powder containing prebiotic B | Active comparator | Dietary Supplement: Probiotic S. salivarius K12 powder containing prebiotic BStreptococcus salivarius K12 powder with prebiotic |
| Probiotic S. salivarius K12 powder containing prebiotic A and B | Active comparator | Dietary Supplement: Probiotic S. salivarius K12 powder containing prebiotics A and BStreptococcus salivarius K12 powder with prebiotic |
| Probiotic S. salivarius M18 lozenges | Active comparator | Dietary Supplement: Probiotic S. salivarius M18 lozengesStreptococcus salivarius M18 lozenge |
| Probiotic S. salivarius M18 lozenges containing prebiotic A | Active comparator | Dietary Supplement: Probiotic S. salivarius M18 lozenges containing prebiotic AStreptococcus salivarius M18 lozenge with prebiotic |
| Probiotic S. salivarius M18 lozenges der containing prebiotic B | Active comparator | Dietary Supplement: Probiotic S. salivarius M18 lozenges containing prebiotic BStreptococcus salivarius M18 lozenge with prebiotic |
| Probiotic S. salivarius M18 + lozenges containing prebiotic A and B | Active comparator | Dietary Supplement: Probiotic S. salivarius M18 + lozenges containing prebiotic A and BStreptococcus salivarius M18 lozenge with prebiotic |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Male or Female 18y - 80y age
- In general good health 18 - 80 years of age.
- Practice good oral hygiene.
Key exclusion criteria (3 listed)
- Have a history of autoimmune disease or are immunocompromised.
- Are on concurrent antibiotic therapy or regular antibiotic use within last 1 week
- History of allergy (e.g. dairy).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Streptococcus salivarius K12 lozengeIn this study, a lozenge will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity. | Dietary supplement | Streptococcus salivarius K12 lozenge |
| Probiotic S. salivarius K12 lozenges containing prebiotic AIn this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity. | Dietary supplement | Probiotic S. salivarius K12 lozenges containing prebiotic A |
| Probiotic S. salivarius K12 lozenges containing prebiotic BIn this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity. | Dietary supplement | Probiotic S. salivarius K12 lozenges containing prebiotic B |
| Probiotic S. salivarius K12 lozenges containing prebiotics A and BIn this study, a lozenge containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity. | Dietary supplement | Probiotic S. salivarius K12 lozenges containing prebiotic A and B |
| Probiotic S. salivarius K12 powderIn this study, a powder will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity | Dietary supplement | Probiotic S. salivarius K12 powder |
| Probiotic S. salivarius K12 powder containing prebiotic AIn this study, a powder containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity | Dietary supplement | Probiotic S. salivarius K12 powder containing prebiotic A |
| Probiotic S. salivarius K12 powder containing prebiotic BIn this study, a powder containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity | Dietary supplement | Probiotic S. salivarius K12 powder containing prebiotic B |
| Probiotic S. salivarius K12 powder containing prebiotics A and BIn this study, a powder containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity | Dietary supplement | Probiotic S. salivarius K12 powder containing prebiotic A and B |
| Probiotic S. salivarius M18 lozengesIn this study, a lozenge containing will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity. | Dietary supplement | Probiotic S. salivarius M18 lozenges |
| Probiotic S. salivarius M18 lozenges containing prebiotic AIn this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity. | Dietary supplement | Probiotic S. salivarius M18 lozenges containing prebiotic A |
| Probiotic S. salivarius M18 lozenges containing prebiotic BIn this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity. | Dietary supplement | Probiotic S. salivarius M18 lozenges der containing prebiotic B |
| Probiotic S. salivarius M18 + lozenges containing prebiotic A and BIn this study, a lozenge containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity. | Dietary supplement | Probiotic S. salivarius M18 + lozenges containing prebiotic A and B |
Primary outcome
Change in microbial colonization from baseline (Day 0) to 1 hour for S. salivarius K12 lozenges
Time frame: 1 hour
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius K12 with or without prebiotics from a lozenge format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to one hour after later across different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
Change in microbial colonization from baseline (Day 0) to 8 hours or S. salivarius K12 lozenges
Time frame: 8 hour
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius K12 with or without prebiotics from a lozenge format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to eight hours after later across different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
Change in microbial colonization from baseline (Day 0) to 24 hours or S. salivarius K12 lozenges
Time frame: 24 hour
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius K12 with or without prebiotics from a lozenge format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to 24 hours after later across different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
Change in microbial colonization from baseline (Day 0) to 48 hours or S. salivarius K12 lozenges
Time frame: 48 hour
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius K12 with or without prebiotics from a lozenge format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to 48hours after later across different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
in microbial colonization from baseline (Day 0) to 1 hour for S. salivarius K12 powder format
Time frame: 1 hour
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius K12 with or without prebiotics from a powder format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to one hour after later across two different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
in microbial colonization from baseline (Day 0) to 8 hour for S. salivarius K12 powder format
Time frame: 8 hours
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius K12 with or without prebiotics from a powder format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to 8 hours after later across two different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
in microbial colonization from baseline (Day 0) to 24 hours for S. salivarius K12 powder format
Time frame: 24 hours
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius K12 with or without prebiotics from a powder format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to 24 hours after later across two different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
in microbial colonization from baseline (Day 0) to 48 hours for S. salivarius K12 powder format
Time frame: 48 hours
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius K12 with or without prebiotics from a powder format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to 48 hours after later across two different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
Change in microbial colonization from baseline (Day 0) to 1 hour for S. salivarius M18 lozenges
Time frame: 1 hour
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius M18 with or without prebiotics from a lozenge format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to one hour after later across different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
Change in microbial colonization from baseline (Day 0) to 8 hours for S. salivarius M18 lozenges
Time frame: 8 hour
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius M18 with or without prebiotics from a lozenge format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to 8 hour after later across different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
Change in microbial colonization from baseline (Day 0) to 24 hours for S. salivarius M18 lozenges
Time frame: 24 hour
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius M18 with or without prebiotics from a lozenge format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to 24 hour after later across different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
Change in microbial colonization from baseline (Day 0) to 48 hours for S. salivarius M18 lozenges
Time frame: 48 hour
Study will determine the change in microbial colonization efficacy of Streptococcus salivarius M18 with or without prebiotics from a lozenge format. The statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to 48 hour after later across different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 May 2022.
- Background: PubMed 17194838Hyink O, Wescombe PA, Upton M, Ragland N, Burton JP, Tagg JR. Salivaricin A2 and the novel lantibiotic salivaricin B are encoded at adjacent loci on a 190-kilobase transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Appl Environ Microbiol. 2007 Feb;73(4):1107-13. doi: 10.1128/AEM.02265-06. Epub 2006 Dec 28.
- Background: PubMed 26781236Burton JP, Chilcott CN, Wescombe PA, Tagg JR. Extended Safety Data for the Oral Cavity Probiotic Streptococcus salivarius K12. Probiotics Antimicrob Proteins. 2010 Oct;2(3):135-44. doi: 10.1007/s12602-010-9045-4.
- Background: PubMed 26855579Gregori G, Righi O, Risso P, Boiardi G, Demuru G, Ferzetti A, Galli A, Ghisoni M, Lenzini S, Marenghi C, Mura C, Sacchetti R, Suzzani L. Reduction of group A beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study. Ther Clin Risk Manag. 2016 Jan 19;12:87-92. doi: 10.2147/TCRM.S96134. eCollection 2016.
- Background: PubMed 23286823Di Pierro F, Adami T, Rapacioli G, Giardini N, Streitberger C. Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults. Expert Opin Biol Ther. 2013 Mar;13(3):339-43. doi: 10.1517/14712598.2013.758711. Epub 2013 Jan 4.
- Background: PubMed 27920580Di Pierro F, Colombo M, Zanvit A, Rottoli AS. Positive clinical outcomes derived from using Streptococcus salivarius K12 to prevent streptococcal pharyngotonsillitis in children: a pilot investigation. Drug Healthc Patient Saf. 2016 Nov 21;8:77-81. doi: 10.2147/DHPS.S117214. eCollection 2016.
- Background: PubMed 27874935Di Pierro F, Colombo M, Giuliani MG, Danza ML, Basile I, Bollani T, Conti AM, Zanvit A, Rottoli AS. Effect of administration of Streptococcus salivarius K12 on the occurrence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old children. Eur Rev Med Pharmacol Sci. 2016 Nov;20(21):4601-4606.
- Background: PubMed 26491371Di Pierro F, Zanvit A, Nobili P, Risso P, Fornaini C. Cariogram outcome after 90 days of oral treatment with Streptococcus salivarius M18 in children at high risk for dental caries: results of a randomized, controlled study. Clin Cosmet Investig Dent. 2015 Oct 3;7:107-13. doi: 10.2147/CCIDE.S93066. eCollection 2015.
- Background: PubMed 32099975Bardellini E, Amadori F, Gobbi E, Ferri A, Conti G, Majorana A. Does Streptococcus Salivarius Strain M18 Assumption Make Black Stains Disappear in Children? Oral Health Prev Dent. 2020 Apr 3;18(2):161-164. doi: 10.3290/j.ohpd.a43359.
- Individual participant dataSharing planned: Yes. Data and information included in the Protocol and Clinical Study Report will be shared to other researchers and/or in publications in due course.
Related trials for Microbial Colonization
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruiting
Expanded Diagnostic Strategy in Older Adults Hospitalized With Community-Acquired Acute Respiratory Infection
Acute Respiratory Infection
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
John D Hale, PhD study director
Blis Technologies Ltd
Rohit Jain, PhD principal investigator
Blis Technologies Ltd, Dunedin, New Zealand
John R Tagg, PhD principal investigator
Blis Technologies Ltd, Dunedin, New Zealand
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Streptococcus salivarius K12 lozenge, Probiotic S. salivarius K12 lozenges containing prebiotic A and Probiotic S. salivarius K12 lozenges containing prebiotic B in people with Microbial Colonization, run by BLIS Technologies Limited at 1 site in New Zealand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 16 May 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in New Zealand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact John D Hale, PhD (+6434740988, john.hale@blis.co.nz), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in microbial colonization from baseline (Day 0) to 1 hour for S. salivarius K12 lozenges (time frame: 1 hour). The study lists 12 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05375383, which also lists 8 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 May 2022.